Zynex Inc ZYXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZYXI is a good fit for your portfolio.
News
-
Zynex Sets First Quarter 2024 Earnings Call
-
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
-
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
-
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
-
Zynex Introduces New Products
-
Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023
-
Zynex Receives FDA Clearance for its Next Generation NMES Device
-
Zynex Recognized in Top 25 Medical Device Companies for 2024
Trading Information
- Previous Close Price
- $11.26
- Day Range
- $11.18–11.53
- 52-Week Range
- $6.88–14.75
- Bid/Ask
- $11.23 / $11.26
- Market Cap
- $358.57 Mil
- Volume/Avg
- 127,688 / 200,540
Key Statistics
- Price/Earnings (Normalized)
- 43.77
- Price/Sales
- 2.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 10.55%
Company Profile
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,101
- Website
- https://www.zynex.com
Comparables
Valuation
|
Metric
|
ZYXI
|
OM
|
PEN
|
|---|---|---|---|
Price/Earnings (Normalized) | 43.77 | — | 138.05 |
Price/Book Value | 8.04 | 1.01 | 6.75 |
Price/Sales | 2.21 | 0.94 | 7.62 |
Price/Cash Flow | 34.30 | — | 45.73 |
Price/Earnings
ZYXI
OM
PEN
Financial Strength
|
Metric
|
ZYXI
|
OM
|
PEN
|
|---|---|---|---|
Quick Ratio | 3.85 | 4.27 | 3.25 |
Current Ratio | 4.74 | 5.26 | 6.06 |
Interest Coverage | 12.50 | −13.39 | 42.88 |
Quick Ratio
ZYXI
OM
PEN
Profitability
|
Metric
|
ZYXI
|
OM
|
PEN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.94% | −39.03% | 5.67% |
Return on Equity (Normalized) | 15.57% | −72.89% | 7.62% |
Return on Invested Capital (Normalized) | 8.83% | −44.98% | 5.96% |
Return on Assets
ZYXI
OM
PEN
Medical Distribution Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MCK
| McKesson Corp | Vhwxlgn | Wnlmy | $69.9 Bil | |
COR
| Cencora Inc | Xcjqmcvb | Vxwmzj | $47.4 Bil | |
CAH
| Cardinal Health Inc | Wlxvyth | Cvysfzp | $25.1 Bil | |
SHTDY
| Sinopharm Group Co Ltd ADR | — | Hkmtzkt | $8.3 Bil | |
SHPMY
| Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H | — | Qpnvbc | $8.2 Bil | |
SHPMF
| Shanghai Pharmaceuticals Holding Co Ltd Class H | — | Xtxxr | $8.1 Bil | |
SHTDF
| Sinopharm Group Co Ltd | — | Cfzdtrg | $7.9 Bil | |
AMFPF
| Amplifon SpA Az nom Post Frazionamento | — | Kkwdphn | $7.7 Bil | |
MAHLY
| Medipal Holdings Corp ADR | — | Kxr | $3.3 Bil | |
MEPDF
| Medipal Holdings Corp | — | Nrzf | $3.3 Bil |